SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
US Defends Drug Companies
Jun 21, 2001
GENEVA - The United States took a tough line yesterday in defense of drug companies' rights to patent protection of their medicines.
Though there were some signs of movement, the overall US stance dismayed the developing countries who cannot afford these drugs and threatened to open a gulf with the European Union.
Yesterday's talks left WTO rules still "unbalanced and tipped firmly in favor of the pharmaceutical giants".
-Phil Bloomer, OxfamThere was disappointment among the 50 developing states present yesterday in Geneva for an unprecedented one-day session of the World Trade Organization, called to discuss their concerns about drug patents.
They had hoped, led by the African countries, that the meeting would agree on a relaxation at least in the interpretation of the rules. This would allow poorer countries to buy cheap medicines from abroad or to make them.
The developing world wants more emphasis on the get-out clauses of the patent rules enshrined in the Trips (trade related intellectual property rights) agreement of the WTO.
The clauses in question theoretically allow a country to buy or make cheap medicines in situations of dire emergency - such as the Aids epidemic. The developing countries want the rules to be interpreted in favor of public health, especially when there is a dispute.
None of the parties - US, EU or the developing world - is calling for Trips to be scrapped, although some campaigners think it should be.
The European Union has sympathy for the developing countries' case. But Carlo Trojan, the EU's senior trade delegate, said the EU favored clarification, not modification of Trips: "My impression is that the council agrees that Trips should be part of the solution, not part of the problem."
Countries that have tried to use the get-out clauses have been intimidated by lawyers for the pharmaceutical giants and the US government in the past. Earlier this year, 39 pharmaceutical companies sued South Africa, which was trying to pass a law allowing it to bring cheap generic medicines from abroad. Amid public outrage, the companies eventually dropped the case.
Buoyed by that victory and a sense that public feeling is on their side in the face of scourges such as Aids, tuberculosis and malaria, the African nations requested yesterday's special session.
Last night the US appeared to be indicating some flexibility on compulsory licensing. This is where a government authorizes companies in its country to make cheap copies of branded drugs locally.
The United States is taking Brazil to the WTO's disputes tribunal, alleging that it has breached the rules by insisting that companies manufacture their drugs in Brazil; this makes them cheaper.
Brazil's delegation said yesterday it was "frustrated and disappointed in particular with the US position, although there was movement in some areas."
Phil Bloomer of Oxfam said yesterday's talks left WTO rules still "unbalanced and tipped firmly in favor of the pharmaceutical giants".
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, The U.S. is on a fast track to authoritarianism like nothing I've ever seen. Meanwhile, corporate news outlets are utterly capitulating to Trump, twisting their coverage to avoid drawing his ire while lining up to stuff cash in his pockets. That's why I believe that Common Dreams is doing the best and most consequential reporting that we've ever done. Our small but mighty team is a progressive reporting powerhouse, covering the news every day that the corporate media never will. Our mission has always been simple: To inform. To inspire. And to ignite change for the common good. Now here's the key piece that I want all our readers to understand: None of this would be possible without your financial support. That's not just some fundraising cliche. It's the absolute and literal truth. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. Will you donate now to help power the nonprofit, independent reporting of Common Dreams? Thank you for being a vital member of our community. Together, we can keep independent journalism alive when it’s needed most. - Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
GENEVA - The United States took a tough line yesterday in defense of drug companies' rights to patent protection of their medicines.
Though there were some signs of movement, the overall US stance dismayed the developing countries who cannot afford these drugs and threatened to open a gulf with the European Union.
Yesterday's talks left WTO rules still "unbalanced and tipped firmly in favor of the pharmaceutical giants".
-Phil Bloomer, OxfamThere was disappointment among the 50 developing states present yesterday in Geneva for an unprecedented one-day session of the World Trade Organization, called to discuss their concerns about drug patents.
They had hoped, led by the African countries, that the meeting would agree on a relaxation at least in the interpretation of the rules. This would allow poorer countries to buy cheap medicines from abroad or to make them.
The developing world wants more emphasis on the get-out clauses of the patent rules enshrined in the Trips (trade related intellectual property rights) agreement of the WTO.
The clauses in question theoretically allow a country to buy or make cheap medicines in situations of dire emergency - such as the Aids epidemic. The developing countries want the rules to be interpreted in favor of public health, especially when there is a dispute.
None of the parties - US, EU or the developing world - is calling for Trips to be scrapped, although some campaigners think it should be.
The European Union has sympathy for the developing countries' case. But Carlo Trojan, the EU's senior trade delegate, said the EU favored clarification, not modification of Trips: "My impression is that the council agrees that Trips should be part of the solution, not part of the problem."
Countries that have tried to use the get-out clauses have been intimidated by lawyers for the pharmaceutical giants and the US government in the past. Earlier this year, 39 pharmaceutical companies sued South Africa, which was trying to pass a law allowing it to bring cheap generic medicines from abroad. Amid public outrage, the companies eventually dropped the case.
Buoyed by that victory and a sense that public feeling is on their side in the face of scourges such as Aids, tuberculosis and malaria, the African nations requested yesterday's special session.
Last night the US appeared to be indicating some flexibility on compulsory licensing. This is where a government authorizes companies in its country to make cheap copies of branded drugs locally.
The United States is taking Brazil to the WTO's disputes tribunal, alleging that it has breached the rules by insisting that companies manufacture their drugs in Brazil; this makes them cheaper.
Brazil's delegation said yesterday it was "frustrated and disappointed in particular with the US position, although there was movement in some areas."
Phil Bloomer of Oxfam said yesterday's talks left WTO rules still "unbalanced and tipped firmly in favor of the pharmaceutical giants".
GENEVA - The United States took a tough line yesterday in defense of drug companies' rights to patent protection of their medicines.
Though there were some signs of movement, the overall US stance dismayed the developing countries who cannot afford these drugs and threatened to open a gulf with the European Union.
Yesterday's talks left WTO rules still "unbalanced and tipped firmly in favor of the pharmaceutical giants".
-Phil Bloomer, OxfamThere was disappointment among the 50 developing states present yesterday in Geneva for an unprecedented one-day session of the World Trade Organization, called to discuss their concerns about drug patents.
They had hoped, led by the African countries, that the meeting would agree on a relaxation at least in the interpretation of the rules. This would allow poorer countries to buy cheap medicines from abroad or to make them.
The developing world wants more emphasis on the get-out clauses of the patent rules enshrined in the Trips (trade related intellectual property rights) agreement of the WTO.
The clauses in question theoretically allow a country to buy or make cheap medicines in situations of dire emergency - such as the Aids epidemic. The developing countries want the rules to be interpreted in favor of public health, especially when there is a dispute.
None of the parties - US, EU or the developing world - is calling for Trips to be scrapped, although some campaigners think it should be.
The European Union has sympathy for the developing countries' case. But Carlo Trojan, the EU's senior trade delegate, said the EU favored clarification, not modification of Trips: "My impression is that the council agrees that Trips should be part of the solution, not part of the problem."
Countries that have tried to use the get-out clauses have been intimidated by lawyers for the pharmaceutical giants and the US government in the past. Earlier this year, 39 pharmaceutical companies sued South Africa, which was trying to pass a law allowing it to bring cheap generic medicines from abroad. Amid public outrage, the companies eventually dropped the case.
Buoyed by that victory and a sense that public feeling is on their side in the face of scourges such as Aids, tuberculosis and malaria, the African nations requested yesterday's special session.
Last night the US appeared to be indicating some flexibility on compulsory licensing. This is where a government authorizes companies in its country to make cheap copies of branded drugs locally.
The United States is taking Brazil to the WTO's disputes tribunal, alleging that it has breached the rules by insisting that companies manufacture their drugs in Brazil; this makes them cheaper.
Brazil's delegation said yesterday it was "frustrated and disappointed in particular with the US position, although there was movement in some areas."
Phil Bloomer of Oxfam said yesterday's talks left WTO rules still "unbalanced and tipped firmly in favor of the pharmaceutical giants".
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.